Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

DIAPHRAGM STRENGTH AND LUNG VOLUMES

NCT07206459 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2024-12-01
Last updated
2025-10-03

Condition(s) studied

Mechanical Ventilation

Investigational drug(s) / intervention(s)

Healthy PatientsCritically Care Patients

Healthy Patients: RESEARCH DESIGN AND METHODS This will be a physiological observational study Study design. Participants will breathe on CPAP with a ventilator. The investigators will deliver the PNS at PEEP levels of zero cmH2O (baseline EELV), zero cmH2O + an abdominal binder (to reduce lung volume), five cmH2O and ten cmH2O. The abdominal binder will be used to achieve an EELV lower than at baseline. At the end of the protocol another PNS at zero cmH2O (baseline EELV) will be performed. Healthy participants will be exposed to the different levels of PEEP from 2 to 5 minutes before each PNS is performed. At every PEEP level, relative changes in EELV (∆z) will be measured with Electrical Impedance Tomography (EIT) to record relative changes in EELV and the electrical activity of the costal diaphragm will be measured using surface electromyography

Critically Care Patients: RESEARCH DESIGN AND METHODS This will be a physiological observational study Study design. For patients. The investigators will perform PNS at the patients own mode of ventilation at their clinical level of PEEP (baseline EELV), PEEP of zero cmH2O (if acceptable for 5 minutes), clinical PEEP ± 2 - 4 cmH2O. At the end of the protocol, another stimulation at the clinical level of PEEP (baseline EELV) will be performed. Patients will be exposed to the different levels of PEEP from 2 to 5 minutes before each PNS is performed.

Study summary

Diaphragm dysfunction (loss of diaphragm strength) is common in the intensive care unit (ICU) patients using ventilators. The diaphragm is the main muscle of respiration and its dysfunction can prolong mechanical ventilation and increase mortality risk. The ventilator settings determine how much air and pressure the patient gets every breath and how much air is left on the lungs after they breathe out. The amount of air left on the lungs influence diaphragm strength measurements which can affect clinical decisions, such as weaning patients off ventilators. This research aims to explore the relationship between the amount of air left in the lungs and diaphragm strength to create a method of correcting measurements of diaphragm strength according to how much air the patients have in the lungs after they breath out. The investigators will test healthy individuals to understand this relationship, then verify if it holds true for ventilated patients by comparing results from both groups.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Inclusion criteria for the healthy participants will be age ≥18 years, no acute or chronic condition impacting respiratory, musculoskeletal or neurological system or that would interfere with the performance of the tests; body mass index \<35 kg/m2 and sufficient English fluency to provide informed consent and to follow the study protocols. * Inclusion criteria for patients will be intubation for more than 6 hours, triggering or not the ventilator (any mode of ventilation). Exclusion Criteria: * Exclusion criteria for the healthy participants will be contraindication for PNS (e.g., cardiac pacemaker or implanted defibrillator, cervical implants), contraindication for a nasogastric tube (e.g., esophageal varices, recent nasal bleeding)and pregnancy. * Exclusion criteria for patients will be primary contraindication for magnetic PNS, severe neurological disorders, pregnancy, current use of continuous neuromuscular blocking agents at the time of the study procedure, P/F ratio \<120, unstable hemodynamics (2 vasopressors), monitored ICP.

Primary outcome measure(s)

  • Change in diaphragm strength — Day 1 (within 5 minutes at each PEEP level during the intervention)
    Change in the pressure generated by the diaphragm (cmH₂O), assessed during end-expiratory occlusion on mechanical ventilation while applying phrenic nerve stimulation. Measurement will be obtained repeatedly on Day 1, between 3-5 minutes after each PEEP adjustment.

Trial sites (1)

FacilityCityRegionStatus
St. Michael's Hospital Toronto Ontario
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07206459 on ClinicalTrials.gov ↗ ← All trials in Canada